Strongbridge Biopharma plc (SBBP) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $15. H.C. Wainwright advised their investors in a research report released on Apr 25, 2016.
Strongbridge Biopharma plc is a biopharmaceutical company focused on the development in-licensing acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. The Companys primary focus has been to build its franchise around rare endocrine disorders which includes product candidates for the treatment of endogenous Cushings syndrome and acromegaly two rare diseases with a high unmet need for treatment options. The Company intends to use a small focused sales force to market its products if approved in the United States European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.